These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 23183108)
1. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor. Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108 [TBL] [Abstract][Full Text] [Related]
2. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase. Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202 [TBL] [Abstract][Full Text] [Related]
4. DBM1285 suppresses tumor necrosis factor alpha production by blocking p38 mitogen-activated protein kinase/mitogen-activated protein kinase-activated protein kinase 2 signaling pathway. Kang JS; Kim HM; Choi IY; Han SB; Yoon YD; Lee H; Park KH; Cho IJ; Lee CW; Lee K; Lee KH; Park SK J Pharmacol Exp Ther; 2010 Aug; 334(2):657-64. PubMed ID: 20427474 [TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation. Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877 [TBL] [Abstract][Full Text] [Related]
6. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. Mourey RJ; Burnette BL; Brustkern SJ; Daniels JS; Hirsch JL; Hood WF; Meyers MJ; Mnich SJ; Pierce BS; Saabye MJ; Schindler JF; South SA; Webb EG; Zhang J; Anderson DR J Pharmacol Exp Ther; 2010 Jun; 333(3):797-807. PubMed ID: 20237073 [TBL] [Abstract][Full Text] [Related]
7. Involvement of p38 MAP kinase in lipopolysaccharide-induced production of pro- and anti-inflammatory cytokines and prostaglandin E(2) in human choriodecidua. Shoji T; Yoshida S; Mitsunari M; Miyake N; Tsukihara S; Iwabe T; Harada T; Terakawa N J Reprod Immunol; 2007 Oct; 75(2):82-90. PubMed ID: 17617469 [TBL] [Abstract][Full Text] [Related]
8. A supercritical CO₂ extract from seabuckthorn leaves inhibits pro-inflammatory mediators via inhibition of mitogen activated protein kinase p38 and transcription factor nuclear factor-κB. Jayashankar B; Mishra KP; Kumar MS; Udayasankar K; Misra K; Ganju L; Singh SB Int Immunopharmacol; 2012 Aug; 13(4):461-7. PubMed ID: 22664145 [TBL] [Abstract][Full Text] [Related]
9. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180 [TBL] [Abstract][Full Text] [Related]
10. Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor. Westra J; Doornbos-van der Meer B; de Boer P; van Leeuwen MA; van Rijswijk MH; Limburg PC Arthritis Res Ther; 2004; 6(4):R384-92. PubMed ID: 15225374 [TBL] [Abstract][Full Text] [Related]
11. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813 [TBL] [Abstract][Full Text] [Related]
12. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase. Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068 [TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells. Grund EM; Kagan D; Tran CA; Zeitvogel A; Starzinski-Powitz A; Nataraja S; Palmer SS Mol Pharmacol; 2008 May; 73(5):1394-404. PubMed ID: 18252806 [TBL] [Abstract][Full Text] [Related]
15. Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats. Bison S; Razzoli M; Arban R; Michielin F; Bertani S; Carboni L Eur J Pharmacol; 2011 Jul; 661(1-3):49-56. PubMed ID: 21545800 [TBL] [Abstract][Full Text] [Related]
16. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. Foey AD; Parry SL; Williams LM; Feldmann M; Foxwell BM; Brennan FM J Immunol; 1998 Jan; 160(2):920-8. PubMed ID: 9551930 [TBL] [Abstract][Full Text] [Related]
17. The identification of a small molecule inhibitor that specifically reduces T cell-mediated adaptive but not LPS-mediated innate immunity by T cell membrane-monocyte contact bioassay. Li YY; Bao M; Meurer J; Skuballa W; Bauman JG; Doecke WD; Zollner TM Immunol Lett; 2008 Apr; 117(1):114-8. PubMed ID: 18241931 [TBL] [Abstract][Full Text] [Related]
18. Second-generation inhibitors demonstrate the involvement of p38 mitogen-activated protein kinase in post-transcriptional modulation of inflammatory mediator production in human and rodent airways. Birrell MA; Wong S; McCluskie K; Catley MC; Hardaker EL; Haj-Yahia S; Belvisi MG J Pharmacol Exp Ther; 2006 Mar; 316(3):1318-27. PubMed ID: 16368902 [TBL] [Abstract][Full Text] [Related]
19. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. Kumar S; Votta BJ; Rieman DJ; Badger AM; Gowen M; Lee JC J Cell Physiol; 2001 Jun; 187(3):294-303. PubMed ID: 11319753 [TBL] [Abstract][Full Text] [Related]
20. Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor. Asano T; Yamazaki H; Kasahara C; Kubota H; Kontani T; Harayama Y; Ohno K; Mizuhara H; Yokomoto M; Misumi K; Kinoshita T; Ohta M; Takeuchi M J Med Chem; 2012 Sep; 55(17):7772-85. PubMed ID: 22905713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]